1.
入组患者基线特征
Baseline characteristics of included patients
| Characteristics | Gefitinib group (n=30) | Erlotinib group (n=31) | P |
| ECOG: Eastern Cooperative Oncology Group; PS: performance status; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor. | |||
| Age (yr) | |||
| Median (range) | 55 (33-74) | 57 (33-77) | 0.519, 3 |
| ≥65 | 10 (33.33%) | 8 (25.81%) | |
| < 65 | 20 (66.67%) | 23 (74.19%) | |
| Gender | 0.715, 0 | ||
| Male | 9 (30.00%) | 8 (25.81%) | |
| Female | 21 (70.00%) | 23 (74.19%) | |
| Smoking status | 0.507, 7 | ||
| Never smoker | 24 (80.00%) | 27 (87.10%) | |
| Current or ever smoker | 6 (20.00%) | 4 (12.90%) | |
| ECOG | 0.899, 8 | ||
| 0-1 | 15 (50.00%) | 15 (48.39%) | |
| ≥2 | 15 (50.00%) | 16 (51.61%) | |
| EGFR mutation | 0.321, 5 | ||
| 19(+) | 19 (63.33%) | 13 (41.94%) | |
| 21(+) | 1 (3.33%) | 1 (3.23%) | |
| Wild | 1 (3.33%) | 3 (9.68%) | |
| Not available | 9 (30.00%) | 14 (45.16%) | |
| Number of metastasized organs | 0.859, 7 | ||
| 1-2 | 20 (66.67%) | 20 (64.52%) | |
| ≥3 | 10 (33.33%) | 11 (35.48%) | |
| Metastasized region | |||
| Lung | 22 (73.33%) | 25 (80.65%) | 0.497, 2 |
| Brain | 15 (50.00%) | 15 (48.39%) | 0.899, 8 |
| Bone | 12 (40.00%) | 15 (48.39%) | 0.509, 7 |
| Liver | 5 (16.67%) | 7 (22.58%) | 0.211, 9 |
| Initial TKI | 0.123, 5 | ||
| 1st line | 11 (36.67%) | 8 (25.81%) | |
| 2nd line | 17 (56.67%) | 15 (48.39%) | |
| ≥3rd line | 2 (6.67%) | 8 (25.81%) | |
| Response of initial TKI | 0.437, 0 | ||
| CR+PR | 23 (76.67%) | 21 (67.74%) | |
| SD | 7 (23.33%) | 10 (32.26%) | |
| PFS of initial TKI | 0.195, 3 | ||
| ≥6 months | 29 (96.67%) | 26 (83.74%) | |
| < 6 months | 1 (3.33%) | 5 (16.13%) | |
| Interval chemotherapy | 0.347, 6 | ||
| Yes | 26 (86.67%) | 24 (77.42%) | |
| No | 4 (13.33%) | 7 (22.58%) | |
| Interval time | 0.785, 0 | ||
| ≥3 months | 25 (83.33%) | 25 (80.65%) | |
| < 3 months | 5 (16.67%) | 6 (19.35%) | |